MX2020006224A - Metodos y terapia combinada para el tratamiento del cancer. - Google Patents

Metodos y terapia combinada para el tratamiento del cancer.

Info

Publication number
MX2020006224A
MX2020006224A MX2020006224A MX2020006224A MX2020006224A MX 2020006224 A MX2020006224 A MX 2020006224A MX 2020006224 A MX2020006224 A MX 2020006224A MX 2020006224 A MX2020006224 A MX 2020006224A MX 2020006224 A MX2020006224 A MX 2020006224A
Authority
MX
Mexico
Prior art keywords
combination therapy
methods
treat cancer
combination
inhibitor
Prior art date
Application number
MX2020006224A
Other languages
English (en)
Inventor
Patrice A Lee
Shannon L Winski
Cristian Massacesi
Christoffel Hendrik Boshoff
Rossano Cesari
Nuzhat Pathan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2020006224A publication Critical patent/MX2020006224A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere a un método para el tratamiento del cáncer mediante la administración de una terapia combinada que comprende una combinación de un inhibidor de MEK y un antagonista de unión al eje PD-1, o una combinación de un inhibidor de MEK y un inhibidor de PARP, o una combinación de un inhibidor de MEK y un antagonista de unión al eje PD-1 y un inhibidor de PARP a un paciente que lo necesita.
MX2020006224A 2017-12-18 2018-12-17 Metodos y terapia combinada para el tratamiento del cancer. MX2020006224A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607190P 2017-12-18 2017-12-18
PCT/IB2018/060181 WO2019123207A1 (en) 2017-12-18 2018-12-17 Methods and combination therapy to treat cancer

Publications (1)

Publication Number Publication Date
MX2020006224A true MX2020006224A (es) 2020-09-03

Family

ID=65237078

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006224A MX2020006224A (es) 2017-12-18 2018-12-17 Metodos y terapia combinada para el tratamiento del cancer.

Country Status (13)

Country Link
US (1) US20210077463A1 (es)
EP (1) EP3727385A1 (es)
JP (1) JP2021507904A (es)
KR (1) KR20200101951A (es)
CN (1) CN111629729A (es)
AU (1) AU2018389196A1 (es)
BR (1) BR112020011287A2 (es)
CA (1) CA3085812A1 (es)
IL (1) IL275517A (es)
MX (1) MX2020006224A (es)
SG (1) SG11202004629PA (es)
TW (1) TW201938165A (es)
WO (1) WO2019123207A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019530704A (ja) * 2016-10-06 2019-10-24 ファイザー・インコーポレイテッド がんの処置のためのアベルマブの投与レジメン
CN111801117A (zh) * 2017-12-27 2020-10-20 特沙诺有限公司 治疗癌症的方法
WO2023064900A1 (en) * 2021-10-15 2023-04-20 Igm Biosciences, Inc. Methods of use of multimeric anti-pd-l1 binding molecules

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
PT2275102E (pt) 2002-03-13 2015-10-27 Array Biopharma Inc Derivados de benzimidazole alquilado n3 como inibidores de mek
ES2625817T3 (es) 2008-08-06 2017-07-20 Medivation Technologies, Inc. Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
JP5883397B2 (ja) 2010-02-03 2016-03-15 ビオマリン プハルマセウトイカル インコーポレイテッド Ｐｔｅｎ欠損に関連した疾患の治療におけるポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のジヒドロピリドフタラジノン阻害剤の使用
KR101826652B1 (ko) 2010-02-08 2018-02-07 메디베이션 테크놀로지즈, 인크. 디히드로피리도프탈라지논 유도체의 합성 방법
TWI557123B (zh) 2010-10-21 2016-11-11 梅迪維新技術公司 結晶型（８Ｓ，９Ｒ）－５－氟－８－（４－氟苯基）－９－（１－甲基－１Ｈ－１，２，４－***－５－基）－８，９－二氫－２Ｈ－吡啶并［４，３，２－ｄｅ］呔－３（７Ｈ）－酮甲苯磺酸鹽
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
US8961970B2 (en) * 2012-03-20 2015-02-24 Novartis Ag Combination therapy
HRP20240033T1 (hr) 2012-10-19 2024-03-29 Array Biopharma, Inc. Formulacija koja sadrži inhibitor mek
US20160280691A1 (en) 2013-11-07 2016-09-29 Biomarin Pharmaceutical Inc. Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
ES2899457T3 (es) * 2014-02-04 2022-03-11 Pfizer Combinación de un antagonista de PD-1 y un inhibidor de VEGFR para tratar el cáncer
US20160009805A1 (en) * 2014-07-11 2016-01-14 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
AU2015296289B2 (en) 2014-07-31 2020-02-27 Medivation Technologies Llc Coformer salts of (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
AU2016333873A1 (en) * 2015-10-06 2018-05-17 The Wistar Institute Of Anatomy And Biology Methods and compositions for treatment of metastatic and refractory cancers and tumors
JP2018536700A (ja) 2015-10-26 2018-12-13 メディヴェイション テクノロジーズ， エルエルシー Ｐａｒｐ阻害剤を用いる小細胞肺がんの治療
GB201704267D0 (en) * 2017-03-17 2017-05-03 Genome Res Ltd Novel biomarker
MA48637A (fr) * 2017-05-09 2021-03-17 Merck Sharp & Dohme Polythérapies pour le traitement du cancer

Also Published As

Publication number Publication date
CA3085812A1 (en) 2019-06-27
CN111629729A (zh) 2020-09-04
EP3727385A1 (en) 2020-10-28
AU2018389196A1 (en) 2020-06-11
SG11202004629PA (en) 2020-07-29
TW201938165A (zh) 2019-10-01
JP2021507904A (ja) 2021-02-25
WO2019123207A1 (en) 2019-06-27
KR20200101951A (ko) 2020-08-28
BR112020011287A2 (pt) 2020-11-24
US20210077463A1 (en) 2021-03-18
IL275517A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
ZA202110554B (en) Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2017005929A (es) Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
MX2018014435A (es) Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2022008868A (es) Tratamiento del cancer con tg02.
EA201490369A1 (ru) Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
MX2017000546A (es) Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek.
MX2017012824A (es) Tratamiento de cáncer de pulmón con inhibidores de glutaminasa.
MX2020011684A (es) Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
MX2019002108A (es) Terapia de combinacion con inhibidores de glutaminasa.
MX2020001727A (es) Terapia de combinacion.
MX2020003361A (es) Combinacion de un inhibidor parp y un antagonista de union al eje pd-1.
MX2019013862A (es) Terapia de combinacion.
MX2017009246A (es) Farmaco de combinacion.
MX2020006224A (es) Metodos y terapia combinada para el tratamiento del cancer.
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
MX2021004709A (es) Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1.